Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Solidifying Atreca’s repertoire

How Atreca parlayed preclinical cancer immunotherapy data into mega-round

Atreca Inc. parlayed preclinical proof-of-concept data from its antibody platform into a $125 million series C round, which will enable the cancer immunotherapy company to bring its two lead programs into the clinic.

An undisclosed, U.S.-based healthcare fund led the untranched round,

Read the full 423 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE